CLINICAL EFFICACY OF ANTI-TUMOR DECOCTION COMBINED WITH CHEMOTHERAPY IN THE TREATMENT OF ADVANCED ORAL CANCER AND ITS EFFECT ON SERUM TUMOR MARKERS, T LYMPHOCYTE SUBSETS AND SURVIVAL RATES OF PATIENTS

Aifang Wang^{1, #,}, Rongrong Li^{2, #}, Ran Li³, Hongyan Qin^{4, *}

¹Department of stomatology, Lixia People’s Hospital of Jinan, Jinan, 250000, Shandong Province, China - 2Department of Anesthesiology and surgery, Jinan Stomatological Hospital, Jinan, 250002, Shandong Province, China - ³Department of stomatology,Qingdao Central Hospital Affiliated to Qingdao University (The Second Clinical Medical College of Qingdao University), Qingdao, 266042, Shandong Province, China - ⁴Medical Records Room, Jinan Authority Hospital, Jinan, 250001, Shandong Province, China 

Objective: To explore the clinical efficacy of anti-tumor decoction combined with chemotherapy in the treatment of advanced oral cancer and its effect on serum tumor markers, T lymphocyte subsets and survival rate of patients. 

Methods: 120 patients with advanced oral cancer admitted to our hospital from January 2019 to January 2020 were selected as the research objects, and equally divided into group A (n = 60) and group B (n = 60) according to different treatment methods. All patients underwent chemotherapy, while group A was additionally treated with anti-tumor decoction to compare the clinical efficacy, survival rates, tumor markers, T lymphocyte subsets, toxic and side effects and oral function between the two groups. 

Results: The objective response rate (ORR) and disease control rate (DCR) in group A were significantly higher than those in group B (P<0.05). The survival rates at 6, 12 and 18 months after treatment in group A were significantly higher than those in group B (P<0.001). The tumor marker levels in group A after treatment were significantly lower than those in group B (P<0.001). The levels of T lymphocyte subsets in group A after treatment were significantly higher than those in group B (P<0.001). The incidence of white blood cell level 2 decline in group A was significantly lower than that in group B (P<0.05). The number of patients with excellent oral function in group A was significantly higher than that in group B (P<0.05). 

Conclusion: Anti-tumor decoction combined with chemotherapy can effectively improve the immune function and reduce the serum tumor marker levels of patients with advanced oral cancer, with a higher survival rate and fewer adverse reactions compared with single chemotherapy, which should be promoted in practice.